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The Brazilian Society of Cardiology (SBC) proposes that hypertensive subjects who use beta-blockers 
and practice physical exercises must have their training heart rate (HR) corrected due to the negative 
chronotropic effect of this drug. Nevertheless, if the physical activity is performed outside of plasmatic 
half-life, correction may not be necessary. This study investigated the exercise chronotropic response both 
inside and outside the beta-blocker plasmatic half-life. Nine subjects in use of atenolol or propranolol, and 
six controls, carried out three walking sessions in three days according to different schedules: EX2 (two 
hours after drug administration, at the plasmatic peak); EX11 (eleven hours after drug administration, 
at the end of plasmatic half-life); and EX23 (twenty-three hours after drug administration, outside 
the plasmatic half-life. The walking sessions were performed on an ergometric treadmill and HR was 
monitored by a heart rate monitor. During the exercises, mean HRs were 97.2, 108.4 and 109 for EX2, 
EX11 and EX23, respectively, with the value for EX2 statistically lower than the others (p<0.05). There 
were no statistical differences in the control group (p>0.05). The study concludes that the attenuation of 
the positive chronotropic response which occurs during exercise in subjects using beta-blockers, is less 
evident when the exercise is performed outside the plasmatic half-life of the drug.
Uniterms: Beta-blockers/negative chronotropic effect. Atenolol. Propanolol. Hypertension. Physical 
exercise. Training heart rate/control.
A Sociedade Brasileira de Cardiologia (SBC) propõe que os hipertensos que utilizam beta-bloqueadores 
e praticam exercícios físicos devem ter sua frequência cardíaca de treinamento (HR) corrigida devido ao 
efeito cronotrópico negativo desse fármaco.  Contudo, se a atividade física é realizada fora da meia-vida 
plasmática do fármaco, a correção pode não ser necessária. Este estudo investigou a resposta cronotrópica 
ao exercício dentro e fora da meia-vida plasmática do beta-bloqueador.  Nove indivíduos que usavam 
atenolol ou propranolol e seis controles, efetuaram três sessões de caminhada em três dias, de acordo 
com diferentes esquemas: EX2 (duas horas após a administração do fármaco, no pico plasmático); 
EX11 (11 horas após a administração do fármaco, no fim da meia-vida plasmática) e EX23 (23 horas 
após a administração do fármaco, fora da meia-vida plasmática). As caminhadas foram realizadas em 
esteira ergométrica e a HR foi monitorada por monitor de freqüência cardíaca. Durante os exercícios, 
as HR médias foram de 97,2, 108,4 e 109, para EX2, EX11 e EX23, respectivamente, com valor de 
EX2 estatisticamente mais baixo do que os outros (p<0,05). Não houve diferenças estatísticas no grupo 
controle (p>0,05). O estudo conclui que a atenuação da resposta cronotrópica positiva, que ocorre 
durante o exercício em indivíduos que utilizam beta-bloqueadores, é menos evidente quando o exercício 
é realizado fora da meia-vida plasmática do fármaco. 
Unitermos: Beta-bloqueadores/efeito cronotrópico negativo. Atenolol. Propranolol. Hipertensão. 
Exercício Físico. Freqüência cardíaca de treinamento/controle.
INTRODUCTION
The practice of regular physical activity is an im-
portant tool in the prevention and non-pharmacological 
treatment of hypertension. Physical activity prescription 
must be done with caution, especially when the patient 
has other concomitant morbidities such as angina and 
heart failure. In addition to these patients being more 
sensitive to cardiovascular changes during their workout, 
they may present reduced physical performance (Baster, 
Basterbroks, 2005; Suzuki, Ohta, 2008; Thompson, 2004).
An important aspect that must be considered in 
physical exercise prescription is the relationship between 
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effectiveness and safety, with intensity being one of the 
main variables involved in assuring this balance. Intensi-
ties that are too low render the exercise ineffective, since 
it does not trigger the cardiovascular adaptations that 
improve the subject’s health. If the intensity is very high 
however, there is an increase in the risk of cardiovascular 
accidents during the exercise (Nelson et al., 2007; Nóbrega 
et al., 1999).
Heart rate monitoring is the most common method 
for supervision of exercise intensity. The efficacy and 
safety of aerobic exercise is guaranteed while training with 
a heart rate of between 60 and 85% of maximal reserve 
heart rate. This rate is called the target-zone (SBC, 2006). 
However, some factors may change the heart 
rate. Beta-blockers (BB) are substances that inhibit the 
β-adrenergic receptors, promoting a negative chrono-
tropic action, observed at rest and during exercise. This 
is characterized by a lower heart rate for the same effort 
intensity, in comparison to a situation of drug abstinence 
(Koshucharova et al., 2001). These drugs are divided into 
three categories: non-selective beta-blockers called first-
generation BBs which block receptors from the subtypes 
called β1 and β2-adrenergic; second-generation BBs, 
which have selective action on the β1 receptor; and third-
generation BBs that, besides β-adrenergic blockade, have 
a vessel expanding action (Pereira-Barreto, 2004; Firmida, 
Mesquita, 2001; Pedersen, Cockcroft, 2007).
Due to the slower increase of heart rate during exer-
cise, the Brazilian Society of Cardiology (1997) suggests 
the use of an equation to correct heart rate values when 
using this variable to monitor exercise intensity. Another 
recommended method in physical exercise prescription to 
these patients is training heart rate determination through 
the ergometer test while under the effect of BB (Vanzelli 
et al., 2005).
Nevertheless, neither the correction equation sug-
gested by the SBC nor the ergometer test under the effect 
of BB consider absorption time, plasmatic half-life, or 
substance elimination time. Likewise, they do not consider 
the time elapsed between administration of the BB and the 
time that the hypertensive subject performs physical exer-
cise. The negative chronotropic effect magnitude may vary 
throughout the day once its concentration peak is obtained 
(approximately one hour after drug ingestion), according 
to the BB pharmacokinetic. In addition, the plasmatic half-
life varies from one to six hours (Couto, 1998). However, 
depending on when the subject performs the physical 
exercise, its prescription with either equation use or the 
ergometer test under the BB effect might be misleading.
Considering these factors, this study tested the hy-
pothesis that the negative chronotropic effects of atenolol 
and propranolol at rest, as well as the attenuation of the 
positive chronotropic effect of the exercise promoted by 
these drugs, vary after administration, according to the 
pharmacodynamics. In this sense, the present study can 
contribute with important information to the establish-
ment of an ideal and safe heart rate zones for hypertensive 
patients, as well as pave the way for new studies, given 
that few studies have investigated the implications of beta-
blocker use in physical exercise prescription.
MATERIAL AND METHODS
Study subjects
This study project was submitted to the Ethics Com-
mittee of the Health Science Center of the Federal Uni-
versity of Paraíba, and was approved under the 1200/07 
Protocol. The subjects were selected, intentionally, at the 
locations where they practiced walking. After an explana-
tion of the research objectives and procedures, those who 
agreed to participate were asked to sign a written informed 
consent form.
 Nine hypertensive subjects were selected, including 
seven females, with mean age of 53.9 years (± 2.8), and 
without renal dysfunction history. Participants had to be 
physically active and practicing aerobic exercises for at 
least three months, on a weekly basis, for three to five 
days a week. They were required to use an adrenergic 
beta-blocker drug in one daily dose, and administer the 
drug only in the first hours of the morning. Seven out of 
nine subjects used atenolol, and two used propranolol at 
doses of 25, 40 and 50 mg. 
The control group comprised six hypertensive wo-
men, not in use of BB, with a mean age of 57.4 years (± 
5.5), who were physically active and fulfilled to the same 
criteria as the experimental group regarding the way they 
exercised. Three subjects used alpha central agonist, two 
used an inhibition agent of angiotensine conversion en-
zyme, and one used an antagonist of AT1 receptors. After 
signing the informed consent form, their dates and times 
of walking were registered. To standardize data collection 
time points, all subjects were asked to administer the drug 
at seven o’clock in the morning. This time was confirmed 
by the subjects’ declaration for each day in which data 
were collected. 
Study design
Each subject carried out three walking sessions of 
forty minutes in duration on alternate days. Three diffe-
rent times were adopted for each day, considering both 
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the time of plasmatic half-life of the beta-blocker drug 
and the point of maximum plasmatic concentration peak. 
Beta-blocker plasmatic half-life is, on average, six hours 
with a concentration peak of about two hours. Considering 
that the subjects took the drug at 7:00 a.m., the exercise 
was practiced two hours (EX2), eleven hours (EX11) and 
twenty-three (EX23) after drug administration. The same 
procedure was used for the control group, as was the order 
in which the exercises were performed. 
Physical Activity Sessions
Before and immediately after each exercise session, 
the blood pressure of each subject was measured by the 
auscultatory method, following the protocol recommended 
by the SBC (2006). The first session conducted was at the 
EX2 point. The subjects carried out a walking exercise on 
a Proaction treadmill, with a minimum velocity control 
of 0.1 km/h and a maximum velocity of 16 km/h. The 
exercise duration was forty minutes, with an intensity of 
between 60 to 80% of the maximal reserve heart rate. A 
period of five minutes was adopted in order to allow the 
treadmill velocity to reach a heart rate compliant with the 
determined intensity, after which a chronometer was used 
to register the forty minutes of exercise. The treadmill ve-
locity in which the heart rate stabilized itself in a training 
zone was registered.
For the EX11 and EX23 sessions, the intensity 
determined was the same velocity obtained in the EX2 
session. This procedure was adopted to guarantee that the 
subjects would do the three sessions with uniform effort 
intensity, in such a way as to permit study of possible heart 
rate changes in response to BB administration.
A heart rate zone compatible with the training target 
zone was determined for the first day of physical exercise 
(EX2), based on the Karvonen equation (1957), defined 
as follows:
THR = HRR + % training (MHR – HRR)
where:
THR = Training heart rate;
HRR = heart rate at rest 
MHR = Maximal heart rate;
% training = training intensity percentage 
The heart rate at rest was measured after the sub-
jects had sat down for ten minutes. For the maximal heart 
rate estimation, we used the Bruce equation (1974) which 
is designed especially for the hypertensive population 
(Bruce et al, apud Robergs and Landwehr, 2002), as 
follows: 
MHR = 204 – 1.07 x age
where:
MHR = estimated maximum heart rate
Additionally, the training heart rate correction equa-
tion for subjects who used BB is as follows: 
% reduction = (Y + 95.58) / 9.74
where:
% reduction = Reduction percentage
Y = Drug dose (mg)
During each of the three exercise sessions, the heart 
rate was measured every two minutes, using an Oregon 
Scientific heart rate monitor with one beat per minute 
precision. 
The exercise sessions were conducted in a controlled 
environment, with temperature of 25 ºC, measured by a 
West Germany thermometer, at a relative air humidity of 
75%, as registered by a G. Huger hygrometer.
The subjects were asked not to do any additional 
physical exercise during this study data collection phase. 
Moreover, the subjects were asked to take their medi-
cation as normal on the days between sessions. For the 
EX23 session, the subjects were requested to bring their 
medicines to the research site, in order to guarantee that it 
would be administered at 7:00 a.m., thereby maintaining 
their daily routine as well as remaining in compliance the 
methodological patterns of the study.
Data Analysis
Data are expressed as mean and standard devia-
tion. The Smirnov-Kolmogorov test was used to test 
data normality, using a significance level of 5%. As this 
procedure indicated that the data did not conform to the 
Gauss curve, a Kruskal-Wallis test was then performed 
to examine the differences between the mean heart rates 
during exercises EX2, EX11 and EX23 (with a confiden-
ce level of 5%). These procedures were developed with 
the aid of an Excel 2003 spreadsheet and the statistical 
software SPSS 13.0. 
RESULTS
The blood pressure at rest for the EX2 session was 
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126.5 ± 7 mmHg for the systolic, and 77.5 ± 8 mmHg 
for the diastolic rates. For EX11, the values of systolic 
and diastolic blood pressure were 130 ± 7 mmHg and 
82 ± 7 mmHg, respectively. The respective values for 
EX23were 129 ± 7 mmHg and 82 ± 8 mmHg. At the end 
of the exercise, the subjects showed an increase in systolic 
pressure of 12.7 ± 7; 14 ± 7; and 8 ± 7 mmHg for the at 
rest values of EX2, EX11 and EX23, respectively. The 
variations of the systolic pressure for these same sessions 
were 2.0 ± 5; -3.3 ± 4; and 4.7 ± 2 mmHg.
Table I presents the heart rate at rest of the subjects 
over the three days of physical exercise. The statistical test 
revealed that there was no significant difference between 
the values of heart rate in the three situations (p>0.05).
The behavior during the physical exercise is sho-
wn in FIGURE 1. A significantly lower heart rate was 
observed during the exercise carried out in the plasmatic 
concentration peak of BB (EX2), compared to EX23, when 
the subjects had not yet administered the drug that day. It 
also differed from EX11, when the active substance was 
already being excreted from the subjects’ body, according 
to the BB pharmacodynamics (Couto, 1998). The differen-
ce between the sessions EX2 and EX23 was 10.9%, while 
in EX11, there was a reduction of 10.3%.
In contrast to the results found in the BB group, the 
subjects of the control group exhibited responses similar to 
the heart rate at rest at ten, twenty, thirty and forty minutes 
of exercise, with no statistical differences between the HR 
measures among the three exercise sessions. Results are 
shown in Figure 2.
Absolute variation of heart rate during exercise was 
observed by subtracting the mean values at ten, twenty, 
thirty and forty minutes from the basal values. Figure 3a, 
shows results in the experimental group, where a statis-
tically significant difference was observed at ten, twenty 
and thirty minutes of exercise in the sessions EX11 and 
EX23, compared to session EX2 (p<0.05). No significant 
difference in the absolute variation of heart rate was found 
among the three sessions in the control group (p>0.05).
 
DISCUSSION
The present study data confirm previous information 
that the BB drug provokes changes in the heart rate which 
interfere in the chronotropic response during physical 
exercise (Wonisch et al., 2003; Stoschitzky et al., 2006; 
TABLE I - Mean values for heart rate at rest, verified immediately 
before the three physical exercise sessions. There was no 
statistical difference among the procedures EX2, EX11 and 
EX23. (HRR-BB = heart rate at rest of the experimental group; 
HRR-CONT = heart rate of the control group; EX2 = physical 
exercise two hours after drug administration; EX11= physical 
exercise eleven hours after drug administration; EX23 = physical 
exercise twenty-three hours after drug administration)
HRR-BB (spm) HRR-CONT
EX2 62 (± 6.8) 82.7 (± 5.9)
EX11 64 (± 7.9) 78.2 (± 5.3)
EX23 64.2 (± 8.9) 80.2 (± 8.0)
FIGURE 1 - Mean behavior of heart rate at rest, at ten, twenty, 
thirty and forty minutes of exercise during the three exercise 
procedures (asterisks indicate differences between HR values 
of procedure EX2, EX11 and EX23 (p<0.05); EX2 = physical 
exercise two hours after drug administration; EX11= physical 
exercise eleven hours after drug administration; EX23 = physical 
exercise twenty-three hours after drug administration.).
FIGURE 2 - Mean behavior of heart rate at ten, twenty, thirty and 
forty minutes of exercise during the three exercise procedures 
in the control group. (There was no statistical difference for 
the heart rates at any of the time points in the three exercise 
sessions (p>0.05); EX2 = physical exercise two hours after drug 
administration; EX11 = physical exercise eleven hours after drug 
administration; EX23 = physical exercise twenty-three hours 
after drug administration).
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Stoschitzky et al., 2004; Derman et al., 1993; Pokan et 
al., 1999; Van Baak, 1988; Tesch, 1985). Nevertheless, 
this study demonstrates for the first time that the chrono-
tropic change induced by beta-blockers does not persist 
throughout the day after being administered, but instead 
is attenuated when the exercise is performed outside the 
BB’s plasmatic half-life. 
The subjects’ arterial pressure was found to be lower 
at the EX2 point, when the drug had reached its plasmatic 
half-life. Although higher than during the other two points, 
these values were always controlled within the parameters 
of 140/90mmHg, as recommended by the SBC (1997). 
Although the exercise had been performed both in and 
outside of beta-blocker plasmatic half-life, the arterial 
pressure response was considered physiological in the 
three exercise sessions.
The control of the treadmill walk velocity, room 
temperature and the relative air humidity eliminates the 
possibility that these variables influenced the heart rate 
differences that were found in the session EX2 (compared 
to EX11 and EX23). The control group data confirm that 
this heart rate variation did not occur due to metabolic, 
neural or hormonal oscillations, but instead resulted from 
the time of day the three exercise sessions were performed.
Derman et al. (1993) reported that atenolol and 
propranolol reduced the heart rate in physical exercise 
by 21.9% and 14.6%, respectively, in comparison to 
other similar exercise sessions conducted without using 
these drugs. These values are greater than the 10.9% and 
10.3% heart rate reduction in the exercises performed at 
eleven and twenty-three hours after the drug was ingested, 
compared to the exercise performed two hours after BB 
administration (plasmatic half-life period) in the present 
study. This smaller chronotropic attenuation may have 
occurred because of the fact that, in the exercises EX11 
and EX23, the subjects were still under some BB effect, 
even though this was outside the plasmatic half-life pe-
riod. Nonetheless, this confirms the hypothesis that the 
chronotropic change induced by BB in exercise depends 
on the time of drug administration and the time chosen to 
perform the exercise. 
Concerning cardiovascular safety, these results 
showed that 100% of the subjects were kept within the 
training zone during the exercise in the EX2 procedure 
(which had the prescription corrected for the BB use). 
In the procedures EX11 and EX23 however, 40% of the 
subjects exceeded the target-zone values. Therefore, the 
present study highlights that the correction equation use 
must be adjusted for time elapsed between drug adminis-
tration and the beginning of physical exercise.
According to Tabet et al. (2006), the use of the 
physical exercise prescription method by means of gene-
ric equations can be misunderstood by subjects who use 
beta-blockers. The most common prescription method by 
professionals is the use of an ergometer test with those 
subjects using BB. From the study results, it is recommen-
ded that exercise is prescribed only based on hypertensive 
subjects using this drug daily (Vanzelli et al., 2004). None-
theless, this policy is also insufficient given that the patient 
may not perform the exercise at the same time point after 
drug administration that the ergometer test was conducted. 
Thus, this procedure proved to be flawed as a correction 
equation, in that it overlooks the time interval between 
drug administration and time of exercise.
Monitoring of heart rate during physical exercise is 
one of the most common methods among physical edu-
cators, while beta-blockers are one of the most prescribed 
anti-hypertensive drugs by physicians. The high preva-
lence of subjects who combine BB and physical exercise 
increases highlights the importance of this study. Against 
this background, it is recommended that these findings 
be widely disseminated among physicians and physical 
educators.
FIGURE 3 - Absolute variation of exercise heart rate for the heart 
rate at rest at ten, twenty, thirty and forty minutes of exercise 
during the three procedures in the experimental group (a) and in 
the control group (b). EX2 = physical exercise two hours after 
drug administration; EX11 = physical exercise eleven hours after 
drug administration; EX23 = physical exercise twenty-three 
hours after drug administration).
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Bearing in mind that this is the first study to ex-
amine the drug’s use in relation to time elapsed between 
administration and beginning of exercise, and taking into 
consideration the large hypertensive population that uses 
BB, it is recommended that further research be conducted 
to increase the knowledge base regarding this phenom-
enon. Several studies have shown that third-generation 
BBs have less impact on heart rate and, consequently, on 
exercise tolerance (Weiss, 2006; Veverka et al., 2006; Ku-
roedov et al., 2004; Van Bortel and Van Baak, 1992). It is 
additionally recommended that new studies be conducted 
involving other third-generation BB, such as carvedilol 
and nebivolol, to determine if there are similar differences 
in the heart rate decrease, as well as to verify the negative 
chronotropic effect at various points in the day.
This study used doses of 25, 40 and 50 mg. However, 
because of the small sample size, it was not possible to 
correlate dose with chronotropic response. Further stud-
ies using a larger sample size are warranted to verify this 
correlation.
These finding emphasize that the chronotropic 
change phenomenon demonstrated by the beta-blockers 
should be studied in order to guarantee exercise prescrip-
tion accuracy and quality among the large hypertensive 
population in use of this drug as part of their anti-hyper-
tensive therapies.
CONCLUSION
By confirming the small positive chronotropic effect 
induced by the BB, this study reinforces the need for heart 
rate correction among hypertensive users of BB, as sug-
gested by Brazilian Society of Cardiology. Nevertheless, 
the data obtained revealed that this chronotropic effect is 
significantly weaker after the plasmatic half-life period, and 
that exercise prescriptions must consider the time interval 
between BB administration and time of exercise activity.
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